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Abstract 
Live plague vaccine (LPV) was widely used to control Yersinia pestis infection in the middle of 20th
century, and this vaccine still remains a choice for prophylaxis of plague. Nevertheless, human immunity 
to LPV was poorly investigated, and was limited mostly to examining the antibody response to the 
capsular antigen F1 and lipopolysaccharide of Y. pestis. In this work we tested sera from 19 individuals 
who received multiple immunizations with attenuated strain of Y. pestis EV NIIEG that is employed as a 
LPV in Russia. Sera from 15 healthy donors, which had no contact with Y. pestis or LPV were used as a 
control. All sera were studied for the presence of antigen-specific antibodies in immunoblot and to a panel 
of highly purified recombinant Y. pestis proteins. We found that donors vaccinated with EV NIIEG 
contained antibodies to one or a few antigens, such as YopM, LcrV, Pla, and F1, in the range of 31.6-
78.9%. However, sera of some non-vaccinated donors reacted positively with at least one of these 
antigens. Similar cross-reactivity was observed earlier during testing of F1/LcrV subunit vaccine in 
humans and non-human primates. In contrast, our study revealed that human humoral immune response 
to YscF was highly specific. Antibodies to this antigen were detected in sera of 10 out of 19 vaccinees, 
while all 15 control sera from non-vaccinated donors were negative. YscF represents a subunit of the 
translocation needle of the type 3 secretion system (T3SS) of Yersinia, and forms a polymeric structure. 
Apparently, successful human vaccination with LPV leads to the assembly of T3SS apparatus in vivo. 
Thus, we showed for the first time that YscF can be considered as a highly specific marker of evaluation 
of human immune response to live plague vaccine.       
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1. Introduction 
The live attenuated strain Y. pestis EV line NIIEG, which is a derivative of the original EV76 
strain of Girard and Robic, has been used as a live plague vaccine for more than 75 years in the former 
Soviet Union. Human vaccination with EV NIIEG could provide a high degree of efficacy against 
infection with Y. pestis [1-6]. The EV NIIEG vaccine holds all known determinants of virulence including 
three typical plasmids pMT1, pCD1 and pPCP1 that provide production of F1 capsule, V antigen and 
Yops, as well as plasminogen activator Pla. The vaccine strain lacks the pigmentation (Pgm) locus due to 
the spontaneous deletion of a 102-kb chromosomal region, containing an iron uptake system involved in 
the virulence process. Thus, human vaccination with this attenuated strain in fact mimics the initial stages 
of infection with Y. pestis, thereby providing guidance in searching for markers of exposure and immunity 
to this pathogen. Generally, this vaccination can elicit in humans both cellular and humoral immunity 
providing protection against all forms of plague, including the most dangerous pneumonic plague [3,4,7, 
8, 9].  
Serologic markers of the human response to vaccination with EV NIIEG are poorly investigated. 
It is not clear whether other antigens, in addition to the established capsular antigen F1 and 
lipopolysaccharide, can elicit specific and long-lasting antibody responses in vaccinees. The anti-F1-
antibody response was routinely used to evaluate the efficacy of EV-based vaccines in humans and 
several animal species inoculated by different routes. The analysis of sera from humans vaccinated 
cutaneously with EV NIIEG for 1 to 30 years revealed the overall presence of antibodies to F1 antigen in 
approximately half of the vaccines [10,11]. Nevertheless, vaccinated individuals who did not possess F1-
specific serum antibodies still may provide a strong T-cell recall to F1 antigen [7]. Apparently, there are 
other immunoreactive Y. pestis-specific antigens that could be potentially used for the development of 
novel plague vaccines. 
 
The aim of the current study was to investigate a humoral immunity in vaccinees who received 
multiple annual immunizations with EV NIIEG to a panel of recombinant Y. pestis-specific antigens, such 
as YopM, YscF, LcrV, F1, and Pla.  
 
2. Methods 
 
Antibody responses were examined in humans, who received multiple (2-49) annual immunizations 
with the live plague vaccine EV NIIEG. To evaluate a long-term immune response to these antigens, we 
chose a cohort of 19 donors, who had their last immunization 4-30 years ago. Also used as a control were 
sera from 15 healthy donors, who had no contact with either Y. pestis, EV NIIEG, or their antigens. The 
presence of the antigen-specific antibodies in the sera of donors was detected by an immunoblotting 
technique. A panel of highly purified recombinant Y. pestis antigens, such as F1, Pla, LcrV, YopM and 
YscF, was obtained after cloning and expression of these proteins in E. coli in the form of fusion peptides 
with His-Tag, followed by their purification by Ni2+- chromatography [7]. 
 
3. Results 
1.1. Specific antibody repertoire to Y. pestis antigens in antisera of vaccinees 
Analysis of the humoral immune response in humans vaccinated with the live vaccine EV NIIEG 
showed that each of the Y. pestis recombinant antigens tested in our study had a certain potency to serve 
as a diagnostic marker for evaluation of antibody response to the plague vaccine. However, these antigens 
significantly differed in their diagnostic value. Indeed, specific antibodies to at least one of the tested 
plague antigens, such as YopM, YscF, LcrV, F1, and Pla (Fig. 1A), could be detected in the vast majority 
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(16 out of 19) of the individual sera (84.2%). Surprisingly, sera of many non-vaccinated donors contained 
a detectable level of antibodies to four out of five tested antigens, namely YopM, LcrV, F1, and Pla. The 
only antigen which displayed a strict specific reaction with sera from vaccinated donors was YscF, a 
subunit of the Yersinia type 3 secretion system needle (Fig. 1B). 
 
(a)                                                                                                       (b) 
 
 
 
 
 
 
 
 
  
 
Fig. 1. Percentage of positive antibody responses to each of recombinant Y. pestis antigens, such as YopM, YscF, LcrV, F1, and Pla, 
detected in immunoblots with sera from vaccinated (a) and non-vaccinated (b) donors.  
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1.2. Specificity of human antisera from vaccinated with LPV EV NIIEG  
 
Positive reaction of Y. pestis recombinant antigens with sera obtained from vaccinated and non-
vaccinated donors is illustrated on Fig. 2A and 2B, respectively. For comparison, we selected donors that 
displayed multiple positive reactions with different antigens. The results of the Western blot demonstrated 
that the strength of the signal obtained with the use of serum from vaccinated donor was comparable with 
that of non-vaccinated individuals (Fig. 2). We found that other serum samples from non-vaccinated 
donors also showed a strong signal in immunoblots to at least one of the antigens, such as YopM, LcrV, 
F1, and Pla. This fact can diminish the significance of these antigens as diagnostic markers. Thus far, sera 
from all 15 non-vaccinated donors tested in this study were negative in reaction with YscF. The strength 
of the signal in immunoblots with sera from vaccinated donors was consistently clear in distinguishing the 
specific reaction with YscF from the background. Due to the small size of the YscF (~10 kDa), its 
detection required running 15% SDS-PAGE (Fig. 2). 
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Fig. 2. Representative immunoblot illustrating positive reaction of human sera from vaccinated (A) and non-vaccinated (B) donors 
with a panel of recombinant antigens of Y. pestis. Antigens were separated in 15% SDS-PAGE for F1 and YscF, and in 12.5% SDS-
PAGE for YopM, LcrV, and Pla. 
 
3. Conclusions 
 
1. Sera obtained from donors immunized with live plague vaccine EV NIIEG contained antibodies to 
different combinations of recombinant antigens of Y. pestis, such as YopM, LcrV, F1, Pla and 
YscF. The latter antigen was the only one which was negative in immunoblots with sera from naïve 
donors (n=15) 
   
2. A highly specific reaction with YscF was detected with sera of 10 out of 19 vaccinated individuals, 
indicating that this antigen can be considered a valuable marker for the evaluation of human 
humoral immune responses to live plague vaccine. 
Acknowledgements 
48   V.A. Feodorova et al. /  Procedia in Vaccinology  7 ( 2013 )  44 – 48 
       This study was supported by the Defense Threat Reduction Agency (DTRA, HDTRA1-11-1-0032) to 
Motin VL, and by the International Science & Technology Center (Project #3853p), and by a subcontract 
with the University of Texas Medical Branch at Galveston (No. 12-096), and in part by the Research 
Programs of The Ministry of Education and Science of Russian Federation (Contract number 
14. 37.21.0563 and the Project number 14.132.21.1312) to Feodorova VA, Lyapina AM, Khizhnyakova 
MA, Konnova SS, Ulianova OV, Polyanina TI. 
References 
[1] Feodorova VA, Pan’kina LN, Savostina EP, Sayapina LV, Motin VL, Dentovskaya SV et al. Yersinia pestis EV NIIEG 
lpxM live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 2007.;25:7620-7628. 
[2] Feodorova VA, Pan’kina LN, Savostina EP, Kuznetsov OV, Konnov NP,. Sayapina LV et al. Pleiotropic effects of the lpxM 
mutation in Yersinia pestis resulting in modification of the biosynthesis of major immunoreactive antigens. Vaccine 
2009;27:2240–2250. 
[3] Feodorova VA, Motin VL. Plague vaccines. In: Feodorova VA, Motin VL, editors. Vaccine Against Bacterial Biothreat 
Pathogens, Kerala, India: Research Signpost; 2011, p. 175-233. 
[4] Feodorova VA, Motin VL. Plague vaccines: current developments and future perspectives. Emerging Microbes and 
Infections 2012;1,e36; doi: 10.1038/emi.2012.34 www.nature.com/emi 
[5] Saltykova RA, Faibich MM. [Experience from a 30-year study of the stability of the properties of the plague vaccine strain 
EV in the USSR.] Zh Mikrobiol 1975;6:3-8. Russian. 
[6] Sun W, Roland KL, Curtiss R, 3rd. Developing live vaccines against plague. J Infect Dev Ctries 2011;5:614-627. 
[7] Braciale VL, Nash M, Sinha N, Zudina IV, Motin VL. Correlates of immunity elicited by live Yersinia pestis vaccine. In:  
Georgiev VS, Western KA, McGowan JJ, editors. National Institute of Allergy and Infectious Diseases, NIH: Frontiers in 
Research, Totowa, NJ, Humana Press; 2008;1:p. 473-80. 
[8] Feodorova VA, Corbel MJ. Prospects for new plague vaccines. Expert Rev Vaccines 2009;8:1721-38. 
[9] Meyer KF, Smith G, Foster LE, Marshall JD, Cavanaugh DC. Plague immunization. IV. Clinical reactions and serologic 
response to inoculations of Haffkine and freeze-dried plague vaccine. J Infect Dis 1974;129:30-6. 
[10] Devdariani ZL, Feodorova VA, Gromova OV, Taranenko TM. Comparative incidence of detection of specific antibodies to 
Yersinia pestis capsular antigen and lipopolysaccharide in humans immunized with pest vaccine. Klin Lab Diagn 1997;4:39-41. 
[11] Feodorova VA, Lyapina AM, Ulianova OV, Lyapina EP, Sayapina LV, Motin VL et al. Serologic markers for long-term 
immunity in humans vaccinated with live Yersinia pestis EV NIIEG. Procedia in Vaccinology 2012;6:10-13. 
